This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

CDKN2A and pancreatic cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

CDKN2Aand pancreatic cancer

  • familial pancreatic cancer (FPC) includes those kindreds that contain at least two first degree relatives with pancreatic ductal adenocarcinoma
    • has been suggested that about 10% of pancreatic cancer has a familial basis (1)
  • CDKN2A gene is situated on chromosome 9p21.3 (1,2)
    • CDKN2A is a tumor suppressor gene that is considered a major cause of familial melanoma
    • germline mutations in the p16/CDKN2A gene cause the Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome, and these individuals have a 13 to 37-fold increased risk of pancreatic cancer (1)
    • in melanoma-prone families of European ancestry, pancreatic cancer is the second most common type of cancers associated with CDKN2A mutations (1)
  • risk of developing pancreatic cancer is also higher in FDRs (first degree relatives) of carriers than in FDRs of non-carriers (RR = 7.4 [95%CI: 2.3-18.7]) (3)

Reference:

  • Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg. 2010;44:293-311. doi:10.1016/j.yasu.2010.05.011
  • Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43(5):548-553. doi:10.1053/j.seminoncol.2016.09.002
  • Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017;6(6):58. doi:10.21037/cco.2017.12.04

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.